GlassScriptPhysician profile
Joshua C Stephens
NPI 1427336841
$7,111.18
in general payments reported to CMS, 2019-2025
42 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $206 · 2021: $247 · 2022: $876 · 2023: $1,268 · 2024: $2,102 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,138.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,132.78 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $903.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $676.95 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $443.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $333.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.58 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.06 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $180.38 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.81 | 2022-2025 | |
| Glaxosmithkline, LLC. | $164.59 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $153.40 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $129.71 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $122.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $122.45 | 2021-2025 | |
| Amgen INC. | $111.13 | 2019-2025 | Otezla, Repatha, Otezla |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.